US › Healthcare

Rein Therapeutics Inc (RNTX)

US · Healthcare · Biotechnology

$0.79+12.41%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.4M

EPS

$-0.10

EPS estimate

$-0.27

EPS came in at -0.10 against a street estimate of -0.27 — a beat of 63.0%.

Key statistics

Market cap

$67.7M

Forward P/E

0.0

P/B

6.64

Book value

$0.12

EPS (TTM)

$-1.68

52-week high

$2.18

52-week low

$0.69

50-day MA

$0.83

200-day MA

$1.15

Beta

1.37

Analyst view

Analysts rate Rein Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $6.00.

Shareholding

Insiders

5.02%

Institutions

52.37%

Largest institutional holders

Fund	Stake
Voss Capital LLC	6.10%
BIOS CAPITAL MANAGEMENT, LP	3.46%
Great Point Partners LLC	2.98%
Citadel Advisors Llc	2.83%
Velan Capital Investment Management LP	1.97%
Prosight Management, LP	1.28%
Vanguard Capital Management, LLC	1.16%
University Of Texas Investment Mgmt Co	0.59%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rein Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.